Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.

Azoulay L, Schneider-Lindner V, Dell'aniello S, Schiffrin A, Suissa S.

Pharmacoepidemiol Drug Saf. 2010 Apr;19(4):335-42. doi: 10.1002/pds.1834.

PMID:
20052677
2.

Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.

Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS.

Metabolism. 2013 Jul;62(7):922-34. doi: 10.1016/j.metabol.2013.01.014. Epub 2013 Feb 16. Review.

PMID:
23419783
3.

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis.

Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN.

Diabetes Obes Metab. 2014 May;16(5):410-7. doi: 10.1111/dom.12233. Epub 2013 Dec 16. Review.

PMID:
24205921
4.

An overview of metformin in the treatment of type 2 diabetes mellitus.

Davidson MB, Peters AL.

Am J Med. 1997 Jan;102(1):99-110. Review.

PMID:
9209206
5.

PURLs: Need an add-on to metformin? Consider this.

Wyncott D, Lyon C, Mounsey A.

J Fam Pract. 2017 Jan;66(1):42-44. Review.

6.

Progressing From Metformin to Sulfonylureas or Meglitinides.

Grant JS, Graven LJ.

Workplace Health Saf. 2016 Sep;64(9):433-9. doi: 10.1177/2165079916644263. Review.

PMID:
27621259
7.

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

Holman RR.

Metabolism. 2006 May;55(5 Suppl 1):S2-5. Review.

PMID:
16631806
8.

Is gliclazide a sulfonylurea with difference? A review in 2016.

Singh AK, Singh R.

Expert Rev Clin Pharmacol. 2016 Jun;9(6):839-51. doi: 10.1586/17512433.2016.1159512. Epub 2016 Mar 15. Review.

PMID:
26924475
9.

Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review.

Chen Y, Du L, Li L, Ma J, Geng X, Yao X, Liu G, Sun X.

J Diabetes. 2017 May;9(5):482-494. doi: 10.1111/1753-0407.12435. Epub 2016 Sep 9. Review.

PMID:
27273872
10.

The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials.

Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitão C, Gross JL.

PLoS Med. 2016 Apr 12;13(4):e1001992. doi: 10.1371/journal.pmed.1001992. eCollection 2016 Apr. Review. Erratum in: PLoS Med. 2016 Jun;13(6):e1002091.

11.

Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.

Wu L, Zhu J, Prokop LJ, Murad MH.

Sci Rep. 2015 Jun 15;5:10147. doi: 10.1038/srep10147. Review.

12.
13.

Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?

Sehra D, Sehra S.

Recent Adv Cardiovasc Drug Discov. 2015;10(1):4-9. Review.

PMID:
26767545
14.

Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.

Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, Kip KE.

Diabetes Care. 2011 Oct;34(10):2323-8. doi: 10.2337/dc11-0512. Review.

15.

Effects of sulfonylureas on tumor growth: a review of the literature.

Pasello G, Urso L, Conte P, Favaretto A.

Oncologist. 2013;18(10):1118-25. doi: 10.1634/theoncologist.2013-0177. Epub 2013 Sep 16. Review.

16.

RCPE UK consensus statement on diabetes.

Anderson A, Boyd K, Christie B, Claridge C, Currie P, Doherty T, Dorward D, Elder A, Hadley-Brown M, Hughes D, Jackson M, Jung R, Marshall S, MacKinnon M, Pollock A, Ritchie L.

J R Coll Physicians Edinb. 2010 Jun;40(2):130-1. doi: 10.4997/JRCPE.2010.S06. No abstract available.

PMID:
21125057
17.

Linagliptin -- Renewed Benefit Assessment According to §35a Paragraph 5b Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2012 Nov 29.

18.

Supplemental Content

Support Center